Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease

Diurnal fluctuations of motor and nonmotor symptoms and a high prevalence of sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian system in the modulation of these symptoms. However, surprisingly little is known regarding circadian function in PD and whether circadian dy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA neurology Jg. 71; H. 4; S. 463
Hauptverfasser: Videnovic, Aleksandar, Noble, Charleston, Reid, Kathryn J, Peng, Jie, Turek, Fred W, Marconi, Angelica, Rademaker, Alfred W, Simuni, Tanya, Zadikoff, Cindy, Zee, Phyllis C
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.04.2014
Schlagworte:
ISSN:2168-6157, 2168-6157
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Diurnal fluctuations of motor and nonmotor symptoms and a high prevalence of sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian system in the modulation of these symptoms. However, surprisingly little is known regarding circadian function in PD and whether circadian dysfunction is involved in the development of sleep-wake disturbances in PD. To determine the relationship between the timing and amplitude of the 24-hour melatonin rhythm, a marker of endogenous circadian rhythmicity, with self-reported sleep quality, the severity of daytime sleepiness, and disease metrics. A cross-sectional study from January 1, 2009, through December 31, 2012, of 20 patients with PD receiving stable dopaminergic therapy and 15 age-matched control participants. Both groups underwent blood sampling for the measurement of serum melatonin levels at 30-minute intervals for 24 hours under modified constant routine conditions at the Parkinson's Disease and Movement Disorders Center of Northwestern University. Twenty-four hour monitoring of serum melatonin secretion. Clinical and demographic data, self-reported measures of sleep quality (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian markers of the melatonin rhythm, including the amplitude, area under the curve (AUC), and phase of the 24-hour rhythm. Patients with PD had blunted circadian rhythms of melatonin secretion compared with controls; the amplitude of the melatonin rhythm and the 24-hour AUC for circulating melatonin levels were significantly lower in PD patients (P < .001). Markers of the circadian phase were not significantly different between the 2 groups. Compared with PD patients without excessive daytime sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score ≥10) had a significantly lower amplitude of the melatonin rhythm and 24-hour melatonin AUC (P = .001). Disease duration, Unified Parkinson's Disease Rating Scale scores, levodopa equivalent dose, and global Pittsburgh Sleep Quality Index score in the PD group were not significantly related to measures of the melatonin circadian rhythm. Circadian dysfunction may underlie excessive sleepiness in PD. The nature of this association needs to be explored further in longitudinal studies. Approaches aimed to strengthen circadian function, such as timed exposure to bright light and exercise, might serve as complementary therapies for the nonmotor manifestations of PD.
AbstractList Diurnal fluctuations of motor and nonmotor symptoms and a high prevalence of sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian system in the modulation of these symptoms. However, surprisingly little is known regarding circadian function in PD and whether circadian dysfunction is involved in the development of sleep-wake disturbances in PD.IMPORTANCEDiurnal fluctuations of motor and nonmotor symptoms and a high prevalence of sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian system in the modulation of these symptoms. However, surprisingly little is known regarding circadian function in PD and whether circadian dysfunction is involved in the development of sleep-wake disturbances in PD.To determine the relationship between the timing and amplitude of the 24-hour melatonin rhythm, a marker of endogenous circadian rhythmicity, with self-reported sleep quality, the severity of daytime sleepiness, and disease metrics.OBJECTIVETo determine the relationship between the timing and amplitude of the 24-hour melatonin rhythm, a marker of endogenous circadian rhythmicity, with self-reported sleep quality, the severity of daytime sleepiness, and disease metrics.A cross-sectional study from January 1, 2009, through December 31, 2012, of 20 patients with PD receiving stable dopaminergic therapy and 15 age-matched control participants. Both groups underwent blood sampling for the measurement of serum melatonin levels at 30-minute intervals for 24 hours under modified constant routine conditions at the Parkinson's Disease and Movement Disorders Center of Northwestern University.DESIGN, SETTING, AND PARTICIPANTSA cross-sectional study from January 1, 2009, through December 31, 2012, of 20 patients with PD receiving stable dopaminergic therapy and 15 age-matched control participants. Both groups underwent blood sampling for the measurement of serum melatonin levels at 30-minute intervals for 24 hours under modified constant routine conditions at the Parkinson's Disease and Movement Disorders Center of Northwestern University.Twenty-four hour monitoring of serum melatonin secretion.INTERVENTIONSTwenty-four hour monitoring of serum melatonin secretion.Clinical and demographic data, self-reported measures of sleep quality (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian markers of the melatonin rhythm, including the amplitude, area under the curve (AUC), and phase of the 24-hour rhythm.MAIN OUTCOMES AND MEASURESClinical and demographic data, self-reported measures of sleep quality (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian markers of the melatonin rhythm, including the amplitude, area under the curve (AUC), and phase of the 24-hour rhythm.Patients with PD had blunted circadian rhythms of melatonin secretion compared with controls; the amplitude of the melatonin rhythm and the 24-hour AUC for circulating melatonin levels were significantly lower in PD patients (P < .001). Markers of the circadian phase were not significantly different between the 2 groups. Compared with PD patients without excessive daytime sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score ≥10) had a significantly lower amplitude of the melatonin rhythm and 24-hour melatonin AUC (P = .001). Disease duration, Unified Parkinson's Disease Rating Scale scores, levodopa equivalent dose, and global Pittsburgh Sleep Quality Index score in the PD group were not significantly related to measures of the melatonin circadian rhythm.RESULTSPatients with PD had blunted circadian rhythms of melatonin secretion compared with controls; the amplitude of the melatonin rhythm and the 24-hour AUC for circulating melatonin levels were significantly lower in PD patients (P < .001). Markers of the circadian phase were not significantly different between the 2 groups. Compared with PD patients without excessive daytime sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score ≥10) had a significantly lower amplitude of the melatonin rhythm and 24-hour melatonin AUC (P = .001). Disease duration, Unified Parkinson's Disease Rating Scale scores, levodopa equivalent dose, and global Pittsburgh Sleep Quality Index score in the PD group were not significantly related to measures of the melatonin circadian rhythm.Circadian dysfunction may underlie excessive sleepiness in PD. The nature of this association needs to be explored further in longitudinal studies. Approaches aimed to strengthen circadian function, such as timed exposure to bright light and exercise, might serve as complementary therapies for the nonmotor manifestations of PD.CONCLUSIONS AND RELEVANCECircadian dysfunction may underlie excessive sleepiness in PD. The nature of this association needs to be explored further in longitudinal studies. Approaches aimed to strengthen circadian function, such as timed exposure to bright light and exercise, might serve as complementary therapies for the nonmotor manifestations of PD.
Diurnal fluctuations of motor and nonmotor symptoms and a high prevalence of sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian system in the modulation of these symptoms. However, surprisingly little is known regarding circadian function in PD and whether circadian dysfunction is involved in the development of sleep-wake disturbances in PD. To determine the relationship between the timing and amplitude of the 24-hour melatonin rhythm, a marker of endogenous circadian rhythmicity, with self-reported sleep quality, the severity of daytime sleepiness, and disease metrics. A cross-sectional study from January 1, 2009, through December 31, 2012, of 20 patients with PD receiving stable dopaminergic therapy and 15 age-matched control participants. Both groups underwent blood sampling for the measurement of serum melatonin levels at 30-minute intervals for 24 hours under modified constant routine conditions at the Parkinson's Disease and Movement Disorders Center of Northwestern University. Twenty-four hour monitoring of serum melatonin secretion. Clinical and demographic data, self-reported measures of sleep quality (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian markers of the melatonin rhythm, including the amplitude, area under the curve (AUC), and phase of the 24-hour rhythm. Patients with PD had blunted circadian rhythms of melatonin secretion compared with controls; the amplitude of the melatonin rhythm and the 24-hour AUC for circulating melatonin levels were significantly lower in PD patients (P < .001). Markers of the circadian phase were not significantly different between the 2 groups. Compared with PD patients without excessive daytime sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score ≥10) had a significantly lower amplitude of the melatonin rhythm and 24-hour melatonin AUC (P = .001). Disease duration, Unified Parkinson's Disease Rating Scale scores, levodopa equivalent dose, and global Pittsburgh Sleep Quality Index score in the PD group were not significantly related to measures of the melatonin circadian rhythm. Circadian dysfunction may underlie excessive sleepiness in PD. The nature of this association needs to be explored further in longitudinal studies. Approaches aimed to strengthen circadian function, such as timed exposure to bright light and exercise, might serve as complementary therapies for the nonmotor manifestations of PD.
Author Peng, Jie
Noble, Charleston
Rademaker, Alfred W
Turek, Fred W
Reid, Kathryn J
Zadikoff, Cindy
Videnovic, Aleksandar
Marconi, Angelica
Simuni, Tanya
Zee, Phyllis C
Author_xml – sequence: 1
  givenname: Aleksandar
  surname: Videnovic
  fullname: Videnovic, Aleksandar
  organization: Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Northwestern University, Chicago, Illinois
– sequence: 2
  givenname: Charleston
  surname: Noble
  fullname: Noble, Charleston
  organization: Department of Neurology, Northwestern University, Chicago, Illinois3Department of Physics, Lund University, Lund, Sweden
– sequence: 3
  givenname: Kathryn J
  surname: Reid
  fullname: Reid, Kathryn J
  organization: Department of Neurology, Northwestern University, Chicago, Illinois
– sequence: 4
  givenname: Jie
  surname: Peng
  fullname: Peng, Jie
  organization: Department of Preventive Medicine, Northwestern University, Chicago, Illinois
– sequence: 5
  givenname: Fred W
  surname: Turek
  fullname: Turek, Fred W
  organization: Department of Neurobiology, Northwestern University, Chicago, Illinois
– sequence: 6
  givenname: Angelica
  surname: Marconi
  fullname: Marconi, Angelica
  organization: Department of Neurology, Northwestern University, Chicago, Illinois
– sequence: 7
  givenname: Alfred W
  surname: Rademaker
  fullname: Rademaker, Alfred W
  organization: Department of Preventive Medicine, Northwestern University, Chicago, Illinois
– sequence: 8
  givenname: Tanya
  surname: Simuni
  fullname: Simuni, Tanya
  organization: Department of Neurology, Northwestern University, Chicago, Illinois
– sequence: 9
  givenname: Cindy
  surname: Zadikoff
  fullname: Zadikoff, Cindy
  organization: Department of Neurology, Northwestern University, Chicago, Illinois
– sequence: 10
  givenname: Phyllis C
  surname: Zee
  fullname: Zee, Phyllis C
  organization: Department of Neurology, Northwestern University, Chicago, Illinois
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24566763$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1LAzEQhoNUbK39ByI5etma76RHKX5BwR70vGQ3E5q6m63Jrth_74IVnMs7vDwMzHOJJrGLgNA1JUtKCL3b29ZGGFLXLBmhfKkYX52hGaPKFIpKPfm3T9Ei5z0ZxxAiuLhAUyakUlrxGdquQ6qtCzbiFhrbdzFEnHbHftdiGx2G7xpyDl-AnT32oQWcG4BDiGOLR3Rr00eIuYvYhQw2wxU697bJsDjlHL0_Prytn4vN69PL-n5TWMlMXzhfaeell5ZbTmshHVDnPGe8qrxaaVoxIZTU43ekMisvDCWcaC0rcJQRYHN0-3v3kLrPAXJftiHX0DSjl27IJZVUG8MENSN6c0KHqgVXHlJobTqWfxbYD2DaZGk
CitedBy_id crossref_primary_10_1007_s11818_024_00450_x
crossref_primary_10_1016_j_neuroscience_2022_09_012
crossref_primary_10_1016_j_chest_2020_09_099
crossref_primary_10_1016_j_sleep_2024_04_020
crossref_primary_10_1007_s12640_024_00716_0
crossref_primary_10_3390_biology10111127
crossref_primary_10_1002_mds_30244
crossref_primary_10_1016_j_heliyon_2024_e24752
crossref_primary_10_1113_jphysiol_2014_284208
crossref_primary_10_3390_ijerph120202071
crossref_primary_10_1038_s41598_019_41248_4
crossref_primary_10_7759_cureus_50948
crossref_primary_10_1186_s40035_023_00340_6
crossref_primary_10_1002_mds_70009
crossref_primary_10_1016_j_nbscr_2016_11_001
crossref_primary_10_3389_frsle_2023_1302021
crossref_primary_10_1016_j_jns_2016_12_062
crossref_primary_10_1007_s40675_017_0079_y
crossref_primary_10_1016_j_autneu_2019_01_009
crossref_primary_10_1007_s00429_019_01921_w
crossref_primary_10_1007_s10522_022_10006_x
crossref_primary_10_1016_j_addr_2025_115645
crossref_primary_10_1016_j_nbscr_2023_100094
crossref_primary_10_1007_s00221_017_5163_5
crossref_primary_10_1007_s12035_024_04400_4
crossref_primary_10_1093_ije_dyy098
crossref_primary_10_1093_sleep_zsaf261
crossref_primary_10_2147_NDT_S465898
crossref_primary_10_1212_WNL_0000000000007078
crossref_primary_10_1007_s00415_020_10353_0
crossref_primary_10_1136_jnnp_2016_314601
crossref_primary_10_1016_j_neuroscience_2020_02_047
crossref_primary_10_1007_s13311_019_00769_6
crossref_primary_10_1146_annurev_pharmtox_010715_103801
crossref_primary_10_1186_s12931_019_1033_y
crossref_primary_10_1016_j_lfs_2020_118512
crossref_primary_10_3389_fpsyt_2021_688890
crossref_primary_10_1016_j_baga_2016_05_001
crossref_primary_10_1093_sleep_zsaa281
crossref_primary_10_1097_01_NT_0000756444_61541_74
crossref_primary_10_1111_aos_13323
crossref_primary_10_1016_j_ncl_2019_04_002
crossref_primary_10_1080_00207454_2023_2292958
crossref_primary_10_1146_annurev_neuro_100322_112249
crossref_primary_10_4103_0366_6999_229889
crossref_primary_10_1007_s11940_014_0304_7
crossref_primary_10_1016_j_cellsig_2020_109904
crossref_primary_10_1007_s00415_024_12730_5
crossref_primary_10_3389_fnagi_2017_00170
crossref_primary_10_1080_14737175_2020_1701437
crossref_primary_10_3233_JPD_212749
crossref_primary_10_1136_jnnp_2020_322875
crossref_primary_10_4103_0366_6999_204920
crossref_primary_10_1002_mdc3_13102
crossref_primary_10_1007_s15005_017_1933_7
crossref_primary_10_1097_NHH_0000000000000398
crossref_primary_10_1002_ctm2_1131
crossref_primary_10_2174_1874467213666200421160835
crossref_primary_10_1016_j_smrv_2016_08_001
crossref_primary_10_1155_2016_3472032
crossref_primary_10_1016_j_jsmc_2025_06_002
crossref_primary_10_1073_pnas_1800314115
crossref_primary_10_1016_j_sleep_2022_08_003
crossref_primary_10_3390_brainsci13060914
crossref_primary_10_1007_s11910_024_01359_6
crossref_primary_10_1016_j_parkreldis_2022_105254
crossref_primary_10_1016_j_jsmc_2017_03_017
crossref_primary_10_1016_j_parkreldis_2023_105891
crossref_primary_10_3389_fneur_2018_00741
crossref_primary_10_1371_journal_pone_0305712
crossref_primary_10_1080_14737175_2025_2450789
crossref_primary_10_1007_s12031_020_01760_z
crossref_primary_10_1111_jsr_12673
crossref_primary_10_1007_s40495_016_0071_0
crossref_primary_10_1093_sleep_zsae247
crossref_primary_10_1007_s10072_022_06188_4
crossref_primary_10_1016_j_brainres_2017_09_027
crossref_primary_10_1038_s41531_025_01042_8
crossref_primary_10_1007_s13311_021_01031_8
crossref_primary_10_1007_s12035_017_0775_0
crossref_primary_10_1186_s40478_019_0845_9
crossref_primary_10_5604_01_3001_0012_7867
crossref_primary_10_1016_j_jsmc_2022_02_003
crossref_primary_10_1016_j_jsmc_2022_02_009
crossref_primary_10_3389_fnagi_2021_736026
crossref_primary_10_3389_fnins_2020_627330
crossref_primary_10_1007_s10522_025_10254_7
crossref_primary_10_1038_s41531_022_00316_9
crossref_primary_10_3389_fnins_2023_1228444
crossref_primary_10_1111_jpi_12759
crossref_primary_10_1007_s10902_024_00838_4
crossref_primary_10_3389_fonc_2022_1009064
crossref_primary_10_1159_000539330
crossref_primary_10_1038_s41386_019_0448_y
crossref_primary_10_3233_JPD_230228
crossref_primary_10_3389_fmed_2021_645293
crossref_primary_10_1016_j_arr_2022_101620
crossref_primary_10_1016_j_addr_2025_115575
crossref_primary_10_1097_WNF_0000000000000573
crossref_primary_10_1002_mds_26592
crossref_primary_10_1002_mds_27200
crossref_primary_10_1126_science_aah4968
crossref_primary_10_1007_s40120_023_00542_0
crossref_primary_10_3389_fnhum_2023_1107061
crossref_primary_10_1210_er_2018_00084
crossref_primary_10_1038_s41583_018_0088_y
crossref_primary_10_1007_s12264_022_00881_2
crossref_primary_10_1016_j_jsmc_2015_08_004
crossref_primary_10_1016_j_sleep_2021_06_023
crossref_primary_10_1007_s40675_017_0078_z
crossref_primary_10_1016_j_arr_2021_101554
crossref_primary_10_1016_j_aca_2021_338764
crossref_primary_10_1172_JCI90328
crossref_primary_10_1016_j_heliyon_2024_e38836
crossref_primary_10_1016_j_jsmc_2015_10_011
crossref_primary_10_1136_jnnp_2020_325546
crossref_primary_10_1016_j_neubiorev_2023_105523
crossref_primary_10_1080_14656566_2024_2422004
crossref_primary_10_1016_j_sleep_2015_06_018
crossref_primary_10_3233_NRE_203075
crossref_primary_10_1016_j_parkreldis_2022_10_011
crossref_primary_10_3389_fneur_2022_765321
crossref_primary_10_1016_S1474_4422_18_30461_7
crossref_primary_10_3389_fnagi_2022_887094
crossref_primary_10_1016_j_jsmc_2017_09_006
crossref_primary_10_1016_j_neurot_2025_e00728
crossref_primary_10_1016_j_jsmc_2017_09_004
crossref_primary_10_1007_s10072_022_06111_x
crossref_primary_10_3390_brainsci12091248
crossref_primary_10_1016_j_neurol_2023_08_008
crossref_primary_10_1093_sleep_zsac165
crossref_primary_10_1038_s41531_025_00942_z
crossref_primary_10_1007_s12264_021_00711_x
crossref_primary_10_1002_jnr_24220
crossref_primary_10_1080_01616412_2017_1315864
crossref_primary_10_1007_s11910_016_0664_3
crossref_primary_10_1172_JCI148286
crossref_primary_10_1038_s41598_022_22381_z
crossref_primary_10_1007_s00415_018_09179_8
crossref_primary_10_1134_S0362119716050170
crossref_primary_10_3389_fphar_2021_650597
crossref_primary_10_3390_ijms232012091
crossref_primary_10_1007_s00018_017_2549_2
crossref_primary_10_1111_jnc_15701
crossref_primary_10_1016_j_smrv_2020_101281
crossref_primary_10_1002_mds_26003
crossref_primary_10_1016_j_arr_2017_09_006
crossref_primary_10_1016_j_sleep_2015_10_019
crossref_primary_10_1016_j_yebeh_2020_107593
crossref_primary_10_1016_j_clinsp_2024_100506
crossref_primary_10_1093_cercor_bhu241
crossref_primary_10_1038_nrneurol_2014_206
crossref_primary_10_1172_JCI148288
crossref_primary_10_1177_0891988719892326
crossref_primary_10_1097_CM9_0000000000001301
crossref_primary_10_3390_biom11030340
crossref_primary_10_3233_JPD_202425
crossref_primary_10_1038_s41598_018_26078_0
crossref_primary_10_1097_MD_0000000000041346
crossref_primary_10_3233_JHD_230567
crossref_primary_10_3389_fnagi_2022_784314
crossref_primary_10_1016_j_sleep_2017_03_026
crossref_primary_10_1177_1877718X251371945
crossref_primary_10_1007_s10072_019_04206_6
crossref_primary_10_1038_s41582_021_00577_7
crossref_primary_10_2147_NDT_S480183
crossref_primary_10_3390_cells13151265
crossref_primary_10_1016_j_parkreldis_2020_03_029
crossref_primary_10_1177_0271678X231164337
crossref_primary_10_1016_j_tins_2024_10_006
crossref_primary_10_1016_S1474_4422_14_70234_0
crossref_primary_10_1016_j_smrv_2018_01_006
crossref_primary_10_1038_s41531_025_01009_9
crossref_primary_10_1111_psyg_12233
crossref_primary_10_1111_ejn_14298
crossref_primary_10_3389_fmolb_2024_1341950
crossref_primary_10_1016_j_smrv_2020_101384
crossref_primary_10_1097_MD_0000000000011298
crossref_primary_10_1016_j_nbd_2017_04_014
crossref_primary_10_1016_j_sleep_2018_07_019
crossref_primary_10_1002_mdc3_12899
crossref_primary_10_1080_13607863_2019_1660852
crossref_primary_10_3389_fneur_2020_00979
crossref_primary_10_1007_s12264_016_0089_7
crossref_primary_10_1002_mdc3_14254
crossref_primary_10_1055_a_2538_3259
crossref_primary_10_1016_j_nbd_2023_106369
crossref_primary_10_3389_fnins_2020_00636
crossref_primary_10_1016_j_neurol_2023_07_005
crossref_primary_10_2147_NSS_S375098
crossref_primary_10_1007_s00210_023_02939_y
crossref_primary_10_1016_j_brainresbull_2019_06_013
crossref_primary_10_1108_ITP_07_2023_0676
crossref_primary_10_1055_s_0045_1804921
crossref_primary_10_3390_cancers13235978
crossref_primary_10_1186_s12964_025_02153_8
crossref_primary_10_1007_s00210_024_03216_2
crossref_primary_10_1177_0748730420934672
crossref_primary_10_1080_14656566_2023_2242786
crossref_primary_10_1093_sleep_zsx041
crossref_primary_10_1089_rej_2020_2388
crossref_primary_10_1016_j_nbscr_2016_12_001
crossref_primary_10_1007_s12035_023_03243_9
crossref_primary_10_3390_metabo15030208
crossref_primary_10_1007_s10072_025_08221_8
crossref_primary_10_1016_j_tem_2016_02_003
crossref_primary_10_1111_jne_70085
crossref_primary_10_1007_s00415_019_09651_z
crossref_primary_10_1016_j_parkreldis_2016_05_012
crossref_primary_10_1111_ejn_15859
crossref_primary_10_1007_s40675_015_0016_x
crossref_primary_10_1007_s13311_020_00938_y
crossref_primary_10_1111_jgs_14493
crossref_primary_10_3390_ijms19123911
crossref_primary_10_3389_fneur_2017_00162
crossref_primary_10_1016_j_nbd_2021_105451
crossref_primary_10_1007_s10072_022_06008_9
crossref_primary_10_1016_j_pneurobio_2019_01_002
crossref_primary_10_1007_s13760_019_01214_3
crossref_primary_10_1111_jpi_12596
crossref_primary_10_3389_fendo_2019_00480
crossref_primary_10_1186_s40035_025_00492_7
crossref_primary_10_1007_s11910_022_01220_8
crossref_primary_10_3389_fpubh_2021_751579
crossref_primary_10_1002_brb3_1880
crossref_primary_10_1016_j_nbd_2020_105029
crossref_primary_10_1016_j_sleep_2020_07_043
crossref_primary_10_3389_fphar_2015_00029
crossref_primary_10_1002_mds_26509
crossref_primary_10_1155_2021_8898887
crossref_primary_10_3389_fnins_2020_00505
crossref_primary_10_3389_fncel_2024_1464595
crossref_primary_10_1001_jamanetworkopen_2021_5713
crossref_primary_10_1002_mds_26865
crossref_primary_10_1007_s00429_017_1439_6
crossref_primary_10_3390_biology12101294
crossref_primary_10_1016_j_ncl_2019_05_001
crossref_primary_10_1097_JNN_0000000000000408
crossref_primary_10_3389_fnins_2022_930514
crossref_primary_10_1016_j_ebiom_2021_103490
crossref_primary_10_1007_s12035_025_05095_x
crossref_primary_10_1016_j_jns_2018_02_032
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1001/jamaneurol.2013.6239
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 2168-6157
ExternalDocumentID 24566763
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: K23 NS072283
– fundername: NCATS NIH HHS
  grantid: UL1 TR000150
– fundername: NIA NIH HHS
  grantid: 5P01 AG011412-17
– fundername: NINDS NIH HHS
  grantid: U01 NS050095
– fundername: NIAAA NIH HHS
  grantid: R01AA020216
– fundername: NINDS NIH HHS
  grantid: U01 NS050095-03
– fundername: NINDS NIH HHS
  grantid: U01 NS050324
– fundername: NINDS NIH HHS
  grantid: U01 NS050324-01A1
– fundername: NHLBI NIH HHS
  grantid: R01 HL105549
– fundername: NIAAA NIH HHS
  grantid: R01 AA020216
GroupedDBID 0R~
4.4
53G
AAGZG
ABIVO
ABJNI
ACDNT
ACGFS
ACPRK
ADBBV
AENEX
AFRAH
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AMJDE
ANMPU
BRYMA
C45
CGR
CUY
CVF
EBD
EBS
ECM
EIF
EJD
EMOBN
EX3
H13
NPM
OB2
OBH
OHH
OVD
PQQKQ
RAJ
SV3
TEORI
WOW
7X8
ADHGD
ID FETCH-LOGICAL-a528t-dfb7df5f5a3a31c45de1ddf323bbf6971b2446572010b89f481030775bed120e2
IEDL.DBID 7X8
ISICitedReferencesCount 279
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000335955100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2168-6157
IngestDate Fri Jul 11 09:20:41 EDT 2025
Thu Jan 02 22:18:53 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a528t-dfb7df5f5a3a31c45de1ddf323bbf6971b2446572010b89f481030775bed120e2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://doi.org/10.1001/jamaneurol.2013.6239
PMID 24566763
PQID 1517882418
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1517882418
pubmed_primary_24566763
PublicationCentury 2000
PublicationDate 2014-04-01
PublicationDateYYYYMMDD 2014-04-01
PublicationDate_xml – month: 04
  year: 2014
  text: 2014-04-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle JAMA neurology
PublicationTitleAlternate JAMA Neurol
PublicationYear 2014
References 16962949 - Eur J Intern Med. 2006 Oct;17(6):417-20
2305266 - Science. 1990 Feb 23;247(4945):975-8
21939733 - Mol Cell Endocrinol. 2012 Feb 5;349(1):91-104
16696576 - CNS Drugs. 2006;20(5):343-50
2162676 - J Neural Transm Gen Sect. 1990;81(1):17-29
10085473 - Biol Signals Recept. 1999 Jan-Apr;8(1-2):120-5
11673578 - Neurology. 2001 Oct 23;57(8):1392-6
20394317 - Sleep. 2010 Apr;33(4):481-90
19811006 - Expert Rev Neurother. 2002 Mar;2(2):249-60
9263193 - Neurobiol Aging. 1997 May-Jun;18(3):285-9
17470494 - Brain. 2007 Jun;130(Pt 6):1577-85
8369102 - J Neural Transm Park Dis Dement Sect. 1993;5(3):227-34
2064730 - J Neural Transm Park Dis Dement Sect. 1991;3(1):41-7
10928569 - Mov Disord. 2000 Jul;15(4):601-3
8475685 - Acta Neurol Scand. 1993 Mar;87(3):171-7
22575905 - Ageing Res Rev. 2013 Jan;12(1):188-200
12420094 - J Neurol. 2002 Nov;249(11):1535-40
18500498 - J Neurol. 2008 Jul;255(7):1032-7
10810544 - Adv Exp Med Biol. 1999;460:425-34
9707350 - Int J Clin Pharmacol Ther. 1998 Jul;36(7):367-9
14572876 - Life Sci. 2003 Nov 14;73(26):3339-49
21075237 - Prog Brain Res. 2010;185:131-53
18042241 - Eur J Neurol. 2008 Jan;15(1):50-4
14598075 - Neurol Sci. 2003 Oct;24(3):178-9
12671525 - Clin Neuropharmacol. 2003 Mar-Apr;26(2):65-72
18175398 - Mov Disord. 2007 Sep;22 Suppl 17:S367-73
6501806 - J Endocrinol Invest. 1984 Aug;7(4):341-5
10682228 - Clin Neuropharmacol. 2000 Jan-Feb;23(1):28-33
16773640 - Mov Disord. 2006 Sep;21(9):1340-2
11718878 - Trends Neurosci. 2001 Dec;24(12):726-31
9827612 - Mov Disord. 1998 Nov;13(6):895-9
25383775 - JAMA Neurol. 2014 Nov;71(11):1455-6
1564476 - J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
19336464 - Brain. 2009 May;132(Pt 5):1128-45
25383776 - JAMA Neurol. 2014 Nov;71(11):1456-7
17960797 - Mov Disord. 2008 Jan;23(1):35-41
18350967 - J Clin Sleep Med. 2008 Feb 15;4(1):66-9
2259351 - Mov Disord. 1990;5(4):280-5
16335481 - Sleep. 2005 Nov;28(11):1365-76
16629763 - Acta Neurol Scand. 2006 May;113(5):288-93
9554572 - J Biol Rhythms. 1998 Apr;13(2):100-12
16780888 - J Neurol Sci. 2006 Oct 25;248(1-2):158-62
2738591 - J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):481-7
12670412 - Curr Treat Options Neurol. 2003 May;5(3):231-239
15634777 - J Neurosci. 2005 Jan 5;25(1):157-63
References_xml – reference: 11673578 - Neurology. 2001 Oct 23;57(8):1392-6
– reference: 12670412 - Curr Treat Options Neurol. 2003 May;5(3):231-239
– reference: 10810544 - Adv Exp Med Biol. 1999;460:425-34
– reference: 14598075 - Neurol Sci. 2003 Oct;24(3):178-9
– reference: 22575905 - Ageing Res Rev. 2013 Jan;12(1):188-200
– reference: 18350967 - J Clin Sleep Med. 2008 Feb 15;4(1):66-9
– reference: 18042241 - Eur J Neurol. 2008 Jan;15(1):50-4
– reference: 16629763 - Acta Neurol Scand. 2006 May;113(5):288-93
– reference: 16962949 - Eur J Intern Med. 2006 Oct;17(6):417-20
– reference: 17960797 - Mov Disord. 2008 Jan;23(1):35-41
– reference: 2162676 - J Neural Transm Gen Sect. 1990;81(1):17-29
– reference: 6501806 - J Endocrinol Invest. 1984 Aug;7(4):341-5
– reference: 15634777 - J Neurosci. 2005 Jan 5;25(1):157-63
– reference: 1564476 - J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
– reference: 16696576 - CNS Drugs. 2006;20(5):343-50
– reference: 9554572 - J Biol Rhythms. 1998 Apr;13(2):100-12
– reference: 18500498 - J Neurol. 2008 Jul;255(7):1032-7
– reference: 2259351 - Mov Disord. 1990;5(4):280-5
– reference: 17470494 - Brain. 2007 Jun;130(Pt 6):1577-85
– reference: 21075237 - Prog Brain Res. 2010;185:131-53
– reference: 10682228 - Clin Neuropharmacol. 2000 Jan-Feb;23(1):28-33
– reference: 9263193 - Neurobiol Aging. 1997 May-Jun;18(3):285-9
– reference: 19336464 - Brain. 2009 May;132(Pt 5):1128-45
– reference: 21939733 - Mol Cell Endocrinol. 2012 Feb 5;349(1):91-104
– reference: 8369102 - J Neural Transm Park Dis Dement Sect. 1993;5(3):227-34
– reference: 16773640 - Mov Disord. 2006 Sep;21(9):1340-2
– reference: 25383775 - JAMA Neurol. 2014 Nov;71(11):1455-6
– reference: 19811006 - Expert Rev Neurother. 2002 Mar;2(2):249-60
– reference: 9827612 - Mov Disord. 1998 Nov;13(6):895-9
– reference: 12671525 - Clin Neuropharmacol. 2003 Mar-Apr;26(2):65-72
– reference: 2738591 - J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):481-7
– reference: 9707350 - Int J Clin Pharmacol Ther. 1998 Jul;36(7):367-9
– reference: 14572876 - Life Sci. 2003 Nov 14;73(26):3339-49
– reference: 10928569 - Mov Disord. 2000 Jul;15(4):601-3
– reference: 12420094 - J Neurol. 2002 Nov;249(11):1535-40
– reference: 16335481 - Sleep. 2005 Nov;28(11):1365-76
– reference: 25383776 - JAMA Neurol. 2014 Nov;71(11):1456-7
– reference: 11718878 - Trends Neurosci. 2001 Dec;24(12):726-31
– reference: 2064730 - J Neural Transm Park Dis Dement Sect. 1991;3(1):41-7
– reference: 18175398 - Mov Disord. 2007 Sep;22 Suppl 17:S367-73
– reference: 2305266 - Science. 1990 Feb 23;247(4945):975-8
– reference: 20394317 - Sleep. 2010 Apr;33(4):481-90
– reference: 10085473 - Biol Signals Recept. 1999 Jan-Apr;8(1-2):120-5
– reference: 8475685 - Acta Neurol Scand. 1993 Mar;87(3):171-7
– reference: 16780888 - J Neurol Sci. 2006 Oct 25;248(1-2):158-62
SSID ssj0000800434
Score 2.5690243
Snippet Diurnal fluctuations of motor and nonmotor symptoms and a high prevalence of sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 463
SubjectTerms Aged
Biomarkers - blood
Circadian Rhythm - physiology
Cohort Studies
Cross-Sectional Studies
Disorders of Excessive Somnolence - epidemiology
Disorders of Excessive Somnolence - metabolism
Disorders of Excessive Somnolence - physiopathology
Female
Humans
Male
Melatonin - secretion
Middle Aged
Parkinson Disease - epidemiology
Parkinson Disease - metabolism
Parkinson Disease - physiopathology
Registries
Severity of Illness Index
Title Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease
URI https://www.ncbi.nlm.nih.gov/pubmed/24566763
https://www.proquest.com/docview/1517882418
Volume 71
WOSCitedRecordID wos000335955100012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbxGu8luk55EisWDLT2o9LZsNgkV7LZ2q9h_70w2rTcRvOxpF8LsZF7fzHyEXDUSl3CtLbOQXrDY5pxpqSzjuqHBHymbeC6Cl0fZ66nBoNUPBbcytFUubKI31GacY438BjwTZGvgb9Tt5J0haxSiq4FCY5XUBIQyqNVyoJY1FoyGYg8s86ipIEtK5HJ6rlo85JdGIgIRiWsIBH6JM72_6Wz_96Q7ZCtEmvSuUo1dsmKLPbLRDVj6Pum3X6e530xAR9gRh3VZOh3OZ8MRzQpD7RdOEIAxpCabIwU9Ld-snfg2eQqv4ry0Hx2jAeQ5IM-d-6f2Awv8CixLuJox47Q0Dn5WJjIR5XFibGSME1xo7ZotGWmO69QkAuZatVyskJNMykRbE_GG5YdkrRgX9phQI0TD6FhKpzQk3E5D2GY41lM0ZLpO18nlQlYp6C-CEiD78UeZ_kirTo4qgaeTatFGiqBsEwzgyR--PiWbcM7QVHNGag5urz0n6_nn7LWcXnjFgGev3_0GxZjDPA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circadian+melatonin+rhythm+and+excessive+daytime+sleepiness+in+Parkinson+disease&rft.jtitle=JAMA+neurology&rft.au=Videnovic%2C+Aleksandar&rft.au=Noble%2C+Charleston&rft.au=Reid%2C+Kathryn+J&rft.au=Peng%2C+Jie&rft.date=2014-04-01&rft.eissn=2168-6157&rft.volume=71&rft.issue=4&rft.spage=463&rft_id=info:doi/10.1001%2Fjamaneurol.2013.6239&rft_id=info%3Apmid%2F24566763&rft_id=info%3Apmid%2F24566763&rft.externalDocID=24566763
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6157&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6157&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6157&client=summon